1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
|
“Heparin: An old drug with a new paradigm”, Jacques L, Science November 2, 1979; Vol. 206,
pp: 528-533.
“Actions of heparin in the atherosclerotic process”, Engelberg H, Pharmacological Reviews
1996; Vol. 488, #2, pp: 327-52.
“Pathogenic factors in vascular dementia and Alzheimer’s disease”, Engelberg H, Dementia in
Geriatric Cognitive Disorders 2004; 18: pp: 278-298.
“Heparin inhibits skeletal muscle growth in vitro”, Kardami E, Spector D, Strohman R,
Developmental Biopsy 1988; 126: pp: 19-28.
“Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin”, Ahmad T,
Garrigo J, Danta I, NEJM July 8,1993; Vol. #2, 329: pp: 90-95.
“Treatment of radiation-induced nervous system injury with heparin and Warfarin”, Glantz M,et
al, Neurology November/1994; Vol. 44: pp: 2020-27.
“A synthetic heparin-mimicking polyanionic compound inhibits central nervous system
inflammation”, Irony-Tur-Sinai M, et al, J. of Neurol. Sci. (2003); 206; pp: 49-57.
“Heparin modulates the single channel kinetics of reconstituted AMPA receptors from rat brain”,
Sinnarajah S, et al, Synapse 1999; 31: pp: 203-209.
“Heparan sulphates up-regulate regeneration with transected sciatic nerves of adult guinea pigs”,
Chau C, Shum D, Chan Y, So K, Eur. J. of Neuroscience 1999; Vol. 11, pp: 1914-26.
“Heparin in Inflammation: Potential Therapeutic Applications beyond Anticoagulation”, Tyrell D, et
al, Advances in Pharmacology 1999; Vol. 46: pp: 151-208.
“Complications of subcutaneous low-dose heparin therapy in neurosurgical patients”, Wen D, Hall
W, Surg. Neurol. December/1998; 50(6): pp: 521-5.
“Heparin-induced thrombocytopenia: what the serologists have taught us”, Kelton J, Warkentin J,
J. Lab Clin. Med.; editorial Vol. 128 #4: pp: 346-48.
“Heparin inhibits induction of nitric oxide synthase by cytokines in rat brain microvascular
endothelial cells”, Bonman E, et al, Neuroscience Letters 1998; 253: pp:95-98.s
|
